NVO Quote, Financials, Valuation and Earnings

Amgen has a net margin of 38.28% compared to Novo Nordisk AS's net margin of 33.28%. Novo Nordisk AS's return on equity of 88.95% beat Amgen's return on equity of 65.35%.

Novo Nordisk AS has a consensus price target of $122.11, signalling upside risk potential of 37.76%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 22.13%. Given that Novo Nordisk AS has higher upside potential than Amgen, analysts believe Novo Nordisk AS is more attractive than Amgen.

Novo Nordisk AS has a beta of 0.400, which suggesting that the stock is 59.967% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.63%. Amgen offers a yield of 3.41% to investors and pays a quarterly dividend of $2.25 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Amgen quarterly revenues of $8.5B. Novo Nordisk AS's net income of $4B is higher than Amgen's net income of $2.8B. Notably, Novo Nordisk AS's price-to-earnings ratio is 28.75x while Amgen's PE ratio is 33.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 10.07x versus 4.38x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Ascendis Pharma AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of -171.53%. Novo Nordisk AS's return on equity of 88.95% beat Ascendis Pharma AS's return on equity of --.

Novo Nordisk AS has a consensus price target of $122.11, signalling upside risk potential of 37.76%. On the other hand Ascendis Pharma AS has an analysts' consensus of $189.82 which suggests that it could grow by 36.97%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.

Novo Nordisk AS has a beta of 0.400, which suggesting that the stock is 59.967% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.529%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.63%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Ascendis Pharma AS quarterly revenues of $63.6M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$109.1M. Notably, Novo Nordisk AS's price-to-earnings ratio is 28.75x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 10.07x versus 22.47x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of -64.14%. Novo Nordisk AS's return on equity of 88.95% beat Evaxion Biotech AS's return on equity of --.

Novo Nordisk AS has a consensus price target of $122.11, signalling upside risk potential of 37.76%. On the other hand Evaxion Biotech AS has an analysts' consensus of -- which suggests that it could grow by 1173.82%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.400, which suggesting that the stock is 59.967% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.63%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Novo Nordisk AS's net income of $4B is higher than Evaxion Biotech AS's net income of -$1.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 28.75x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 10.07x versus 1.26x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 38.28% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 88.95% beat Viking Therapeutics's return on equity of --.

Novo Nordisk AS has a consensus price target of $122.11, signalling upside risk potential of 37.76%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 159.92%. Given that Viking Therapeutics has higher upside potential than Novo Nordisk AS, analysts believe Viking Therapeutics is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.400, which suggesting that the stock is 59.967% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.63%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Viking Therapeutics quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Viking Therapeutics's net income of -$24.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 28.75x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 10.07x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.